As the hyperglycemia and disrupted immunological adaptations during pregnancy are responsible for increased maternal-fetal morbidity, as well as the short- and long-term complications in mothers and offspring [1, 22, 23], improving glycemic control by insulin therapy may substantially reduce the risks of these maternal and neonatal outcomes of diabetes in pregnancy [24–26]. This evidence concerns the gene INS and diabetes mellitus.